Annals of Hematology

, Volume 94, Issue 5, pp 813–823 | Cite as

Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab

  • N. L. Berinstein
  • S. Bhella
  • N. M. Pennell
  • M. C. Cheung
  • K. R. Imrie
  • D. E. Spaner
  • V. Milliken
  • L. Zhang
  • K. Hewitt
  • A. Boudreau
  • M. D. Reis
  • A. Chesney
  • D. Good
  • Z. Ghorab
  • L. K. Hicks
  • E. Piliotis
  • R. Buckstein
Original Article

Abstract

Three sequential phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous transplant (high-dose therapy and autologous stem cell transplantation (HDT/ASCT)) for recurrent follicular lymphoma. Seventy-three patients were enrolled from 1996 to 2009. Patients received HDT/ASCT combined with (1) interferon-α 3 MU/m2 subcutaneously (SC) three times per week (TIW) for 2 years post-ASCT, (2) rituximab (R) 375 mg/m2 for in vivo purging 3–5 days pre-stem cell collection and 2 × 4 weekly R at 2 and 6 months post-ASCT, respectively, or (3) three infusions of R pre-stem cell collection followed by 6× R weekly and interferon-α 3 MU/m2 SC TIW. Although not statistically significant, progression-free survival (PFS) for patients who received rituximab was 56.4 and 49.1 % at 5 and 10 years compared to 36 and 21 % in those who did not receive rituximab. Molecular relapse post-HDT/ASCT was the strongest predictor of PFS in a multivariate analysis. Molecular relapse was coincident with or preceded clinical relapses in 84 % of patients who relapsed—median of 12 months (range 0–129 months). Adverse events included secondary malignancy, transformation to diffuse large B cell lymphoma, prolonged mostly asymptomatic hypogammaglobulinemia, and pulmonary fibrosis. The long-term toxicity profile must be considered when selecting patients for this treatment.

Keywords

Stem cell transplantation Immunotherapy Follicular lymphoma Prolonged remission 

Supplementary material

277_2014_2288_MOESM1_ESM.docx (37 kb)
ESM 1(Supplemental file) Kaplan-Meier Survival curves for OS and PFS: A) OS for all patients, B) OS for each of the three trials was not significantly different (P = 0.2496), C) PFS for all patients, D) PFS for each of the three trials was not significantly different (P = 0.1263) (DOCX 36 kb)

References

  1. 1.
    Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, McDiarmid S, Huebsch LB (2007) A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 13(8):956–964. doi:10.1016/j.bbmt.2007.04.009 CrossRefPubMedGoogle Scholar
  2. 2.
    Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS (2005) Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ann Hematol 84(8):526–531. doi:10.1007/s00277-005-1058-9 CrossRefPubMedGoogle Scholar
  3. 3.
    Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM (2000) The CUP trial: a randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 11(Suppl 1):91–94CrossRefPubMedGoogle Scholar
  4. 4.
    Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 21(21):3918–3927. doi:10.1200/JCO.2003.10.023 CrossRefPubMedGoogle Scholar
  5. 5.
    Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS (2007) Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25(18):2554–2559. doi:10.1200/JCO.2006.09.8327 CrossRefPubMedGoogle Scholar
  6. 6.
    Peters AC, Duan Q, Russell JA, Duggan P, Owen C, Stewart DA (2011) Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Leuk Lymphoma 52(11):2124–2129. doi:10.3109/10428194.2011.594925 CrossRefPubMedGoogle Scholar
  7. 7.
    Foster M, Gabriel DA, Shea T (2009) Role of hematopoietic stem cell transplant in the management of follicular lymphoma. Oncologist 14(7):726–738. doi:10.1634/theoncologist. 2009-0045 CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, Solal-Celigny P, Coiffier B (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620. doi:10.1200/JCO.2007.15.5358 CrossRefPubMedGoogle Scholar
  9. 9.
    Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111(8):4004–4013. doi:10.1182/blood-2007-10-116749 CrossRefPubMedGoogle Scholar
  10. 10.
    Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramee JF, Arakelyan N, Thyss A, Molucon-Chabrot C, Delepine R, Milpied N, Colombat P, Deconinck E (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5):995–1001. doi:10.1182/blood-2008-05-160200 CrossRefPubMedGoogle Scholar
  11. 11.
    Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96(8):1128–1135. doi:10.3324/haematol.2010.030320 CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M (2005) Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23(26):6394–6399. doi:10.1200/JCO.2005.07.019 CrossRefPubMedGoogle Scholar
  13. 13.
    Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M (2012) Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 104(1):18–28. doi:10.1093/jnci/djr450 CrossRefPubMedGoogle Scholar
  14. 14.
    Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To B, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozak T, Dreger P, Uddin R, Ruiz de Elvira C, Goldstone AH (2013) Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 31(13):1624–1630. doi:10.1200/JCO.2012.47.1862 CrossRefPubMedGoogle Scholar
  15. 15.
    Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G (1986) High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 104(2):163–168CrossRefPubMedGoogle Scholar
  16. 16.
    Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L, Imrie K, Spaner D, Cheung MC, Boudreau A, Reis M, Crump M, Berinstein NL (2009) Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 43(9):701–708. doi:10.1038/bmt.2008.382 CrossRefPubMedGoogle Scholar
  17. 17.
    Pennell N, Woods A, Reis M, Buckstein R, Spaner D, Imrie K, Hewitt K, Boudreau A, Seth A, Berinstein NL (2006) Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction. J Mol Diagn 8(1):40–50. doi:10.2353/jmoldx.2006.050050 CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJM (2007) Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611PubMedGoogle Scholar
  19. 19.
    Allison PD, SAS Institute (2010) Survival analysis using SAS: a practical guide, 2nd edn. SAS Institute, CaryGoogle Scholar
  20. 20.
    Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 89(4):605–611. doi:10.1038/sj.bjc.6601120 CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA (2013) Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica 98(4):620–625. doi:10.3324/haematol.2012.069583 CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M (2008) Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 19(7):1331–1335. doi:10.1093/annonc/mdn044 CrossRefPubMedGoogle Scholar
  23. 23.
    Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23(10):2215–2223. doi:10.1200/JCO.2005.06.146 CrossRefPubMedGoogle Scholar
  24. 24.
    Gribben JG, Hosing C, Maloney DG (2011) Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant 17(1, Supplement):S63–S70. doi:10.1016/j.bbmt.2010.10.011 CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Witzens-Harig M, Dreger P (2010) Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 51(6):967–974. doi:10.3109/10428191003793341 CrossRefPubMedGoogle Scholar
  26. 26.
    Lim SH, Esler WV, Zhang Y, Zhang J, Periman PO, Burris C, Townsend M (2008) B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 49(1):152–153. doi:10.1080/10428190701742506 CrossRefPubMedGoogle Scholar
  27. 27.
    Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D, Pruitt B, Hancock P, Townsend M (2005) Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 35(2):207–208. doi:10.1038/sj.bmt.1704742 CrossRefPubMedGoogle Scholar
  28. 28.
    Shortt J, Spencer A (2006) Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin’s lymphoma. Bone Marrow Transplant 38(6):433–436. doi:10.1038/sj.bmt.1705463 CrossRefPubMedGoogle Scholar
  29. 29.
    Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Yamaguchi K, Takeda Y, Goto H, Sato N, Koizumi K, Mukai M, Koike T (2007) Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 137(4):349–354. doi:10.1111/j.1365-2141.2007.06584.x CrossRefPubMedGoogle Scholar
  30. 30.
    Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB (2012) Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma 53(6):1130–1136. doi:10.3109/10428194.2011.645208 CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Litam JP, Dail DH, Spitzer G, Vellekoop L, Verma DS, Zander AR, Dicke KA (1981) Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 65(1–2):39–44PubMedGoogle Scholar
  32. 32.
    Till BG, Madtes DK (2012) BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma 53(6):1019–1020. doi:10.3109/10428194.2011.654341 CrossRefPubMedGoogle Scholar
  33. 33.
    Ghesquieres H (2014) Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks. Leuk Lymphoma:1-2. doi: 10.3109/10428194.2014.974597
  34. 34.
    Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, Crump M, Kuruvilla J (2014) Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma:1-19. doi:10.3109/10428194.2014.963075
  35. 35.
    Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122(23):3759–3766. doi:10.1182/blood-2013-06-507319 CrossRefPubMedGoogle Scholar
  36. 36.
    Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P (2009) Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 20(4):722–728. doi:10.1093/annonc/mdn691 CrossRefPubMedGoogle Scholar
  37. 37.
    Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M (2012) A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Ann Oncol 23(10):2687–2695. doi:10.1093/annonc/mds202 CrossRefPubMedGoogle Scholar
  38. 38.
    Neumann F, Harmsen S, Martin S, Kronenwett R, Kondakci M, Aivado M, Germing U, Haas R, Kobbe G (2006) Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol 85(8):530–534. doi:10.1007/s00277-006-0113-5 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • N. L. Berinstein
    • 1
    • 4
    • 5
    • 7
  • S. Bhella
    • 2
    • 4
  • N. M. Pennell
    • 3
  • M. C. Cheung
    • 1
    • 4
  • K. R. Imrie
    • 1
    • 4
  • D. E. Spaner
    • 1
    • 4
    • 5
  • V. Milliken
    • 1
  • L. Zhang
    • 1
  • K. Hewitt
    • 1
  • A. Boudreau
    • 1
  • M. D. Reis
    • 3
  • A. Chesney
    • 3
  • D. Good
    • 3
  • Z. Ghorab
    • 3
  • L. K. Hicks
    • 6
  • E. Piliotis
    • 1
    • 4
  • R. Buckstein
    • 1
    • 4
  1. 1.Department of Hematology/Oncology, Odette Cancer CentreSunnybrook Health Sciences CentreTorontoCanada
  2. 2.Department of HematologyPrincess Margaret HospitalTorontoCanada
  3. 3.Department of Laboratory MedicineSunnybrook Health Sciences CentreTorontoCanada
  4. 4.Department of MedicineUniversity of TorontoTorontoCanada
  5. 5.Department of ImmunologyUniversity of TorontoTorontoCanada
  6. 6.Department of HematologySt. Michael’s HospitalTorontoCanada
  7. 7.Translational Research, Ontario Institute for Cancer ResearchMaRS CentreTorontoCanada

Personalised recommendations